Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 79 entries
Sorted by: Best Match Show Resources per page
A risk-based approach to cumulative effect assessments for marine management.

The Science of the total environment

Stelzenmüller V, Coll M, Mazaris AD, Giakoumi S, Katsanevakis S, Portman ME, Degen R, Mackelworth P, Gimpel A, Albano PG, Almpanidou V, Claudet J, Essl F, Evagelopoulos T, Heymans JJ, Genov T, Kark S, Micheli F, Pennino MG, Rilov G, Rumes B, Steenbeek J, Ojaveer H.
PMID: 28892857
Sci Total Environ. 2018 Jan 15;612:1132-1140. doi: 10.1016/j.scitotenv.2017.08.289. Epub 2017 Sep 08.

Marine ecosystems are increasingly threatened by the cumulative effects of multiple human pressures. Cumulative effect assessments (CEAs) are needed to inform environmental policy and guide ecosystem-based management. Yet, CEAs are inherently complex and seldom linked to real-world management processes....

Cite
Stelzenmüller V, Coll M, Mazaris AD, et al. A risk-based approach to cumulative effect assessments for marine management. Sci Total Environ. 2017;612:1132-1140doi: 10.1016/j.scitotenv.2017.08.289.
Stelzenmüller, V., Coll, M., Mazaris, A. D., Giakoumi, S., Katsanevakis, S., Portman, M. E., Degen, R., Mackelworth, P., Gimpel, A., Albano, P. G., Almpanidou, V., Claudet, J., Essl, F., Evagelopoulos, T., Heymans, J. J., Genov, T., Kark, S., Micheli, F., Pennino, M. G., Rilov, G., Rumes, B., Steenbeek, J., & Ojaveer, H. (2018). A risk-based approach to cumulative effect assessments for marine management. The Science of the total environment, 6121132-1140. https://doi.org/10.1016/j.scitotenv.2017.08.289
Stelzenmüller, Vanessa, et al. "A risk-based approach to cumulative effect assessments for marine management." The Science of the total environment vol. 612 (2018): 1132-1140. doi: https://doi.org/10.1016/j.scitotenv.2017.08.289
Stelzenmüller V, Coll M, Mazaris AD, Giakoumi S, Katsanevakis S, Portman ME, Degen R, Mackelworth P, Gimpel A, Albano PG, Almpanidou V, Claudet J, Essl F, Evagelopoulos T, Heymans JJ, Genov T, Kark S, Micheli F, Pennino MG, Rilov G, Rumes B, Steenbeek J, Ojaveer H. A risk-based approach to cumulative effect assessments for marine management. Sci Total Environ. 2018 Jan 15;612:1132-1140. doi: 10.1016/j.scitotenv.2017.08.289. Epub 2017 Sep 08. PMID: 28892857.
Copy Download .nbib Format: NLM
Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay.

BMJ open

Guzman JD, Evangelopoulos D, Gupta A, Birchall K, Mwaigwisya S, Saxty B, McHugh TD, Gibbons S, Malkinson J, Bhakta S.
PMID: 23794563
BMJ Open. 2013 Jun 20;3(6). doi: 10.1136/bmjopen-2013-002672.

OBJECTIVES: Lead antituberculosis (anti-TB) molecules with novel mechanisms of action are urgently required to fuel the anti-TB drug discovery pipeline. The aim of this study was to validate the use of the high-throughput spot culture growth inhibition (HT-SPOTi) assay...

Cite
Guzman JD, Evangelopoulos D, Gupta A, et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open. 2013;3(6)doi: 10.1136/bmjopen-2013-002672.
Guzman, J. D., Evangelopoulos, D., Gupta, A., Birchall, K., Mwaigwisya, S., Saxty, B., McHugh, T. D., Gibbons, S., Malkinson, J., & Bhakta, S. (2013). Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ open, 3(6), . https://doi.org/10.1136/bmjopen-2013-002672
Guzman, Juan D, et al. "Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay." BMJ open vol. 3,6 (2013). doi: https://doi.org/10.1136/bmjopen-2013-002672
Guzman JD, Evangelopoulos D, Gupta A, Birchall K, Mwaigwisya S, Saxty B, McHugh TD, Gibbons S, Malkinson J, Bhakta S. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open. 2013 Jun 20;3(6). doi: 10.1136/bmjopen-2013-002672. PMID: 23794563; PMCID: PMC3693423.
Copy Download .nbib Format: NLM
The commercial impact of pig Salmonella spp. infections in border-free markets during an economic recession.

Veterinary world

Evangelopoulou G, Kritas S, Christodoulopoulos G, Burriel AR.
PMID: 27047083
Vet World. 2015 Mar;8(3):257-72. doi: 10.14202/vetworld.2015.257-272. Epub 2015 Mar 05.

The genus Salmonella, a group of important zoonotic pathogens, is having global economic and political importance. Its main political importance results from the pathogenicity of many of its serovars for man. Serovars Salmonella Enteritidis and Salmonella Typhimurium are currently...

Cite
Evangelopoulou G, Kritas S, Christodoulopoulos G, et al. The commercial impact of pig Salmonella spp. infections in border-free markets during an economic recession. Vet World. 2015;8(3):257-72doi: 10.14202/vetworld.2015.257-272.
Evangelopoulou, G., Kritas, S., Christodoulopoulos, G., & Burriel, A. R. (2015). The commercial impact of pig Salmonella spp. infections in border-free markets during an economic recession. Veterinary world, 8(3), 257-72. https://doi.org/10.14202/vetworld.2015.257-272
Evangelopoulou, G, et al. "The commercial impact of pig Salmonella spp. infections in border-free markets during an economic recession." Veterinary world vol. 8,3 (2015): 257-72. doi: https://doi.org/10.14202/vetworld.2015.257-272
Evangelopoulou G, Kritas S, Christodoulopoulos G, Burriel AR. The commercial impact of pig Salmonella spp. infections in border-free markets during an economic recession. Vet World. 2015 Mar;8(3):257-72. doi: 10.14202/vetworld.2015.257-272. Epub 2015 Mar 05. PMID: 27047083; PMCID: PMC4774829.
Copy Download .nbib Format: NLM
Body Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite Levels.

ISRN neurology

Markianos M, Evangelopoulos ME, Koutsis G, Davaki P, Sfagos C.
PMID: 24205443
ISRN Neurol. 2013 Sep 24;2013:981070. doi: 10.1155/2013/981070. eCollection 2013.

Body weight and height of patients with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome suggesting MS (CIS) in the age range 18 to 60 years (154 males and 315 females) were compared with those of subjects (146 males...

Cite
Markianos M, Evangelopoulos ME, Koutsis G, et al. Body Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite Levels. ISRN Neurol. 2013;2013:981070doi: 10.1155/2013/981070.
Markianos, M., Evangelopoulos, M. E., Koutsis, G., Davaki, P., & Sfagos, C. (2013). Body Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite Levels. ISRN neurology, 2013981070. https://doi.org/10.1155/2013/981070
Markianos, Manolis, et al. "Body Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite Levels." ISRN neurology vol. 2013 (2013): 981070. doi: https://doi.org/10.1155/2013/981070
Markianos M, Evangelopoulos ME, Koutsis G, Davaki P, Sfagos C. Body Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite Levels. ISRN Neurol. 2013 Sep 24;2013:981070. doi: 10.1155/2013/981070. eCollection 2013. PMID: 24205443; PMCID: PMC3800568.
Copy Download .nbib Format: NLM
Serum leptin levels in treatment-naive patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis.

Autoimmune diseases

Evangelopoulos ME, Koutsis G, Markianos M.
PMID: 25505980
Autoimmune Dis. 2014;2014:486282. doi: 10.1155/2014/486282. Epub 2014 Nov 19.

Several studies have investigated leptin levels in patients with multiple sclerosis (MS) with somewhat conflicting results. They have all focused on patients with established relapsing-remitting (RR) MS but have not specifically looked at patients with clinically isolated syndrome (CIS)...

Cite
Evangelopoulos ME, Koutsis G, Markianos M. Serum leptin levels in treatment-naive patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis. Autoimmune Dis. 2014;2014:486282doi: 10.1155/2014/486282.
Evangelopoulos, M. E., Koutsis, G., & Markianos, M. (2014). Serum leptin levels in treatment-naive patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis. Autoimmune diseases, 2014486282. https://doi.org/10.1155/2014/486282
Evangelopoulos, Maria Eleftheria, et al. "Serum leptin levels in treatment-naive patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis." Autoimmune diseases vol. 2014 (2014): 486282. doi: https://doi.org/10.1155/2014/486282
Evangelopoulos ME, Koutsis G, Markianos M. Serum leptin levels in treatment-naive patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis. Autoimmune Dis. 2014;2014:486282. doi: 10.1155/2014/486282. Epub 2014 Nov 19. PMID: 25505980; PMCID: PMC4254075.
Copy Download .nbib Format: NLM
Humoral immune activation in amyotrophic lateral sclerosis patients.

Neurology international

Rentzos M, Evangelopoulos ME, Sereti E, Zouvelou V, Marmara S, Alexakis T, Evdokimidis I.
PMID: 23717782
Neurol Int. 2013 Feb 11;5(1):e3. doi: 10.4081/ni.2013.e3. Print 2013 Feb 11.

There is evidence that immunological factors may involved in the pathogenetic mechanisms of amyotrophic lateral sclerosis (ALS). Few studies to date have explored the status of the humoral immune response in patients with ALS. We examined the presence of...

Cite
Rentzos M, Evangelopoulos ME, Sereti E, et al. Humoral immune activation in amyotrophic lateral sclerosis patients. Neurol Int. 2013;5(1):e3doi: 10.4081/ni.2013.e3.
Rentzos, M., Evangelopoulos, M. E., Sereti, E., Zouvelou, V., Marmara, S., Alexakis, T., & Evdokimidis, I. (2013). Humoral immune activation in amyotrophic lateral sclerosis patients. Neurology international, 5(1), e3. https://doi.org/10.4081/ni.2013.e3
Rentzos, Michael, et al. "Humoral immune activation in amyotrophic lateral sclerosis patients." Neurology international vol. 5,1 (2013): e3. doi: https://doi.org/10.4081/ni.2013.e3
Rentzos M, Evangelopoulos ME, Sereti E, Zouvelou V, Marmara S, Alexakis T, Evdokimidis I. Humoral immune activation in amyotrophic lateral sclerosis patients. Neurol Int. 2013 Feb 11;5(1):e3. doi: 10.4081/ni.2013.e3. Print 2013 Feb 11. PMID: 23717782; PMCID: PMC3661984.
Copy Download .nbib Format: NLM
Computerized tomographic morphometric analysis of the cervical spine.

The open orthopaedics journal

Evangelopoulos D, Kontovazenitis P, Kouris S, Zlatidou X, Benneker L, Vlamis J, Korres D, Efstathopoulos N.
PMID: 22802920
Open Orthop J. 2012;6:250-4. doi: 10.2174/1874325001206010250. Epub 2012 Jun 29.

BACKGROUND: Detailed knowledge of cervical canal and transverse foramens' morphometry is critical for understanding the pathology of certain diseases and for proper preoperative planning. Lateral x-rays do not provide the necessary accuracy. A retrospective morphometric study of the cervical...

Cite
Evangelopoulos D, Kontovazenitis P, Kouris S, et al. Computerized tomographic morphometric analysis of the cervical spine. Open Orthop J. 2012;6:250-4doi: 10.2174/1874325001206010250.
Evangelopoulos, D., Kontovazenitis, P., Kouris, S., Zlatidou, X., Benneker, L., Vlamis, J., Korres, D., & Efstathopoulos, N. (2012). Computerized tomographic morphometric analysis of the cervical spine. The open orthopaedics journal, 6250-4. https://doi.org/10.2174/1874325001206010250
Evangelopoulos, Ds, et al. "Computerized tomographic morphometric analysis of the cervical spine." The open orthopaedics journal vol. 6 (2012): 250-4. doi: https://doi.org/10.2174/1874325001206010250
Evangelopoulos D, Kontovazenitis P, Kouris S, Zlatidou X, Benneker L, Vlamis J, Korres D, Efstathopoulos N. Computerized tomographic morphometric analysis of the cervical spine. Open Orthop J. 2012;6:250-4. doi: 10.2174/1874325001206010250. Epub 2012 Jun 29. PMID: 22802920; PMCID: PMC3395889.
Copy Download .nbib Format: NLM
Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course.

Therapeutic advances in neurological disorders

Zoehner G, Miclea A, Salmen A, Kamber N, Diem L, Friedli C, Bagnoud M, Ahmadi F, Briner M, Sédille-Mostafaie N, Kilidireas C, Stefanis L, Chan A, Hoepner R, Evangelopoulos ME.
PMID: 31632461
Ther Adv Neurol Disord. 2019 Sep 27;12:1756286419878340. doi: 10.1177/1756286419878340. eCollection 2019.

BACKGROUND: In multiple sclerosis (MS), the frequency of hypogammaglobulinemia is unknown. We aimed to evaluate the frequency of reduced immunoglobulin (Ig) concentrations and its association with immunotherapy and disease course in two independent MS cohorts.METHODS: In our retrospective cross-sectional...

Cite
Zoehner G, Miclea A, Salmen A, et al. Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Ther Adv Neurol Disord. 2019;12:1756286419878340doi: 10.1177/1756286419878340.
Zoehner, G., Miclea, A., Salmen, A., Kamber, N., Diem, L., Friedli, C., Bagnoud, M., Ahmadi, F., Briner, M., Sédille-Mostafaie, N., Kilidireas, C., Stefanis, L., Chan, A., Hoepner, R., & Evangelopoulos, M. E. (2019). Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Therapeutic advances in neurological disorders, 121756286419878340. https://doi.org/10.1177/1756286419878340
Zoehner, Greta, et al. "Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course." Therapeutic advances in neurological disorders vol. 12 (2019): 1756286419878340. doi: https://doi.org/10.1177/1756286419878340
Zoehner G, Miclea A, Salmen A, Kamber N, Diem L, Friedli C, Bagnoud M, Ahmadi F, Briner M, Sédille-Mostafaie N, Kilidireas C, Stefanis L, Chan A, Hoepner R, Evangelopoulos ME. Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Ther Adv Neurol Disord. 2019 Sep 27;12:1756286419878340. doi: 10.1177/1756286419878340. eCollection 2019. PMID: 31632461; PMCID: PMC6767745.
Copy Download .nbib Format: NLM
Tobacco Treatment Guideline for High Risk Groups: A pilot study in patients with Chronic Obstructive Pulmonary Disease.

Tobacco induced diseases

Trofor AC, Papadakis S, Lotrean L, Buculei-Porosnicu I, Vyzikidou VK, Evangelopoulou V, Vardavas C, Behrakis P.
PMID: 31516413
Tob Induc Dis. 2018 Apr 12;16:13. doi: 10.18332/tid/85944. eCollection 2018.

INTRODUCTION: Smoking cessation is a key clinical intervention for reducing progressive lung destruction and lung function deterioration in patients with Chronic Obstructive Pulmonary Disease (COPD). Specialised Tobacco Cessation Guidelines for High-risk Groups (TOB-G) were developed and published in 2017...

Cite
Trofor AC, Papadakis S, Lotrean L, et al. Tobacco Treatment Guideline for High Risk Groups: A pilot study in patients with Chronic Obstructive Pulmonary Disease. Tob Induc Dis. 2018;16:13doi: 10.18332/tid/85944.
Trofor, A. C., Papadakis, S., Lotrean, L., Buculei-Porosnicu, I., Vyzikidou, V. K., Evangelopoulou, V., Vardavas, C., & Behrakis, P. (2018). Tobacco Treatment Guideline for High Risk Groups: A pilot study in patients with Chronic Obstructive Pulmonary Disease. Tobacco induced diseases, 1613. https://doi.org/10.18332/tid/85944
Trofor, Antigona C, et al. "Tobacco Treatment Guideline for High Risk Groups: A pilot study in patients with Chronic Obstructive Pulmonary Disease." Tobacco induced diseases vol. 16 (2018): 13. doi: https://doi.org/10.18332/tid/85944
Trofor AC, Papadakis S, Lotrean L, Buculei-Porosnicu I, Vyzikidou VK, Evangelopoulou V, Vardavas C, Behrakis P. Tobacco Treatment Guideline for High Risk Groups: A pilot study in patients with Chronic Obstructive Pulmonary Disease. Tob Induc Dis. 2018 Apr 12;16:13. doi: 10.18332/tid/85944. eCollection 2018. PMID: 31516413; PMCID: PMC6659489.
Copy Download .nbib Format: NLM
A pilot study of the Tobacco Treatment Guidelines for High-Risk Groups (TOB-G) for pregnant and postpartum women.

European journal of midwifery

Papadakis S, Vyzikidou VK, Vivilaki VG, Vardavas CI, Loukopoulou AN, Peleki T, Evangelopoulou V, Behrakis P.
PMID: 33537577
Eur J Midwifery. 2018 Nov 28;2:16. doi: 10.18332/ejm/99543. eCollection 2020.

INTRODUCTION: Maternal smoking constitutes a significant risk to the fetus and is associated with multiple adverse pregnancy outcomes. Despite this, an estimated 6-19% of women in Europe smoke during pregnancy. We conducted a pilot study to examine the feasibility...

Cite
Papadakis S, Vyzikidou VK, Vivilaki VG, et al. A pilot study of the Tobacco Treatment Guidelines for High-Risk Groups (TOB-G) for pregnant and postpartum women. Eur J Midwifery. 2018;2:16doi: 10.18332/ejm/99543.
Papadakis, S., Vyzikidou, V. K., Vivilaki, V. G., Vardavas, C. I., Loukopoulou, A. N., Peleki, T., Evangelopoulou, V., & Behrakis, P. (2020). A pilot study of the Tobacco Treatment Guidelines for High-Risk Groups (TOB-G) for pregnant and postpartum women. European journal of midwifery, 216. https://doi.org/10.18332/ejm/99543
Papadakis, Sophia, et al. "A pilot study of the Tobacco Treatment Guidelines for High-Risk Groups (TOB-G) for pregnant and postpartum women." European journal of midwifery vol. 2 (2020): 16. doi: https://doi.org/10.18332/ejm/99543
Papadakis S, Vyzikidou VK, Vivilaki VG, Vardavas CI, Loukopoulou AN, Peleki T, Evangelopoulou V, Behrakis P. A pilot study of the Tobacco Treatment Guidelines for High-Risk Groups (TOB-G) for pregnant and postpartum women. Eur J Midwifery. 2018 Nov 28;2:16. doi: 10.18332/ejm/99543. eCollection 2020. PMID: 33537577; PMCID: PMC7839106.
Copy Download .nbib Format: NLM
Type I interferon detection in autoimmune diseases: challenges and clinical applications.

Expert review of clinical immunology

Papadopoulos VE, Skarlis C, Evangelopoulos ME, Mavragani CP.
PMID: 34096436
Expert Rev Clin Immunol. 2021 Aug;17(8):883-903. doi: 10.1080/1744666X.2021.1939686. Epub 2021 Aug 25.

INTRODUCTION: Accumulating data highlights that the dysregulation of type I interferon (IFN) pathways plays a central role in the pathogenesis of several systemic and organ-specific autoimmune diseases. Advances in understanding the role of type I IFNs in these disorders...

Cite
Papadopoulos VE, Skarlis C, Evangelopoulos ME, et al. Type I interferon detection in autoimmune diseases: challenges and clinical applications. Expert Rev Clin Immunol. 2021;17(8):883-903doi: 10.1080/1744666X.2021.1939686.
Papadopoulos, V. E., Skarlis, C., Evangelopoulos, M. E., & Mavragani, C. P. (2021). Type I interferon detection in autoimmune diseases: challenges and clinical applications. Expert review of clinical immunology, 17(8), 883-903. https://doi.org/10.1080/1744666X.2021.1939686
Papadopoulos, Vassilis E, et al. "Type I interferon detection in autoimmune diseases: challenges and clinical applications." Expert review of clinical immunology vol. 17,8 (2021): 883-903. doi: https://doi.org/10.1080/1744666X.2021.1939686
Papadopoulos VE, Skarlis C, Evangelopoulos ME, Mavragani CP. Type I interferon detection in autoimmune diseases: challenges and clinical applications. Expert Rev Clin Immunol. 2021 Aug;17(8):883-903. doi: 10.1080/1744666X.2021.1939686. Epub 2021 Aug 25. PMID: 34096436.
Copy Download .nbib Format: NLM
Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.

Therapeutic advances in neurological disorders

Vakrakou AG, Tzanetakos D, Evangelopoulos ME, Argyrakos T, Tzartos JS, Anagnostouli M, Andreadou E, Koutsis G, Velonakis G, Toulas P, Gialafos E, Dimitrakopoulos A, Psimenou E, Stefanis L, Kilidireas C.
PMID: 34046086
Ther Adv Neurol Disord. 2021 May 18;14:17562864211006503. doi: 10.1177/17562864211006503. eCollection 2021.

AIMS: Our goal was to expand the spectrum of clinico-radiologic characteristics and the possible therapeutic choices in patients with tumefactive demyelinating lesions (TDLs).METHODS: A retrospective analysis of 50 patients with at least one TDL was performed at an academic...

Cite
Vakrakou AG, Tzanetakos D, Evangelopoulos ME, et al. Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases. Ther Adv Neurol Disord. 2021;14:17562864211006503doi: 10.1177/17562864211006503.
Vakrakou, A. G., Tzanetakos, D., Evangelopoulos, M. E., Argyrakos, T., Tzartos, J. S., Anagnostouli, M., Andreadou, E., Koutsis, G., Velonakis, G., Toulas, P., Gialafos, E., Dimitrakopoulos, A., Psimenou, E., Stefanis, L., & Kilidireas, C. (2021). Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases. Therapeutic advances in neurological disorders, 1417562864211006503. https://doi.org/10.1177/17562864211006503
Vakrakou, Aigli G, et al. "Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases." Therapeutic advances in neurological disorders vol. 14 (2021): 17562864211006503. doi: https://doi.org/10.1177/17562864211006503
Vakrakou AG, Tzanetakos D, Evangelopoulos ME, Argyrakos T, Tzartos JS, Anagnostouli M, Andreadou E, Koutsis G, Velonakis G, Toulas P, Gialafos E, Dimitrakopoulos A, Psimenou E, Stefanis L, Kilidireas C. Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases. Ther Adv Neurol Disord. 2021 May 18;14:17562864211006503. doi: 10.1177/17562864211006503. eCollection 2021. PMID: 34046086; PMCID: PMC8135218.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 79 entries